We have set out on a journey to change the drug development process for the better so patients can get the treatments they desperately need and not have to wait years for them to become available. Michael L. Shuler Hesperos’ CEO and Co-Founder, Dr. Michael Shuler, was recently interviewed by Jason Hartman with Thrive Global … Read more
Dr. James J. Hickman elected as Fellow of the National Acadamy of Inventors Hesperos is excited to announce that Chief Scientist, Dr. James J. Hickman, has been elected fellow of the National Academy of Inventors (NAI). This year’s class included 175 innovators from around the world – all of which will be inducted and honored … Read more
Human-on-a-chip System for Use in Therapeutic Index Determination and Systemic Toxicity in Pre-clinical Drug Discovery Presented at AAPS 2020 by James J. Hickman, PhD Chief Scientist, Hesperos, Inc.
THE SCIENCE AND TECHNOLOGY PLATFORM THAT COULD
The Tech Tribune, the journalistic arm of Crunchbase, recently selected Hesperos as one of the top 10 technology startups in Orlando. We are proud to be listed among the best companies in the City Beautiful. Award recipients cover a wide range of industries and were selected based on several factors including revenue potential and leadership … Read more
Unraveling the pathologic role of skeletal muscle in ALS A key challenge in developing effective therapies for amyotrophic lateral sclerosis has been a poor understanding of the disease pathology. To address this issue, a team of scientists from University of Central Florida and Hesperos have created a new ALS skeletal muscle Human-on-a-Chip® model which could … Read more
UCF/HESPEROS RESEARCHERS UTILIZE HUMAN-ON-A-CHIP® APPROACH TO MODEL ALS PATHOLOGY Key Findings Data supports use of functional neuromuscular junction (NMJ) system to evaluate amyotrophic lateral sclerosis pathology First study to validate the use of Deanna protocol in a human system as a strategy for treating ALS Press Release ORLANDO, Fla. — The Hybrid Systems Lab at … Read more
— New publication in Advanced Science validates potential use in evaluating certain immune responses in drug discovery and systemic diseases, including Coronavirus Disease 2019 (COVID-19)— — Hesperos’ immune system-on-a-chip features recirculating immune cells with the key organ mimics heart, skeletal muscle and liver ORLANDO, Fla. – June 2, 2020 — Hesperos Inc., pioneers of the … Read more
PRECLINICAL STAGES OF ALZHEIMER’S DISEASE AND MILD COGNITIVE IMPAIRMENT MODELED WITH HESPEROS HUMAN-ON-A-CHIP® SYSTEM — Peer-reviewed publication in Alzheimer’s & Dementia: Translational Research & Clinical Interventions validates potential of drug discovery platform and ability to study early stages of disease pathology — ORLANDO, Fla. – May 28, 2020 – Hesperos Inc., pioneers of the Human-on-a-Chip® … Read more
HUMAN-ON-A-CHIP FOR RARE DISEASES DISCUSSION In our latest publication, UCF & Hesperos researchers discuss how Human-on-a-chip systems can be used to address the unique challenges facing rare diseases. Researchers cite that rare diseases are “limited by the high cost of research and low target population.” Further Discussion of Human-on-a-chip® technology Researchers further discuss how “Human-on-a-chip … Read more